Hepatitis E virus ORF Z peptides
AssigneesGenelabs Technologies, Inc., The United States of America as represented by the Department of Health and Human Services
InventorsGregory R. Reyes, Daniel W. Bradley, Jr-Shin Twu, Michael A. Purdy, Albert W. Tam, Krzysztof Z. Krawczynski, Patrice O. Yarbough
Life of this patent
Estimating the term…
Abstract
An antigen composition hepatitis E virus (HEV) infection are disclosed. The antigen composition includes peptides corresponding to carboxyl terminal end regions of the second and third open reading frames of the HEV genome.
Claims1
An isolated HEV peptide selected from the group consisting of peptides identified by the sequences SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO.18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, and SEQ ID NO.22.
Dependencies are inferred from the claim text.